home / stock / cvm / cvm news

CVM News and Press, Cel-Sci Corporation From 10/24/23

Stock Information
Company Name: Cel-Sci Corporation
Stock Symbol: CVM
Market: NYSE
Website: cel-sci.com
Menu
CVM CVM Quote CVM Short CVM News CVM Articles CVM Message Board
Get CVM Alerts

News, Short Squeeze, Breakout and More Instantly...
CVM - ATXG, NUWE and MTC among pre-market losers

2023-10-24 08:23:16 ET Losers: INVO Bioscience ( INVO ) -19% . Markforged Holding Corporation ( MKFG ) -18 % schedules third Quarter 2023 earnings announcement ; provides preliminary third Quarter results and updates 2023 revenue guidance. IonQ ( IONQ...
CVM - CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

View the video: https://youtu.be/23WqSM9gI40 CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congres...

CVM - CEL-SCI climbs after ESMO data for lead asset Multikine

2023-10-23 15:35:21 ET More on Cel-Sci Seeking Alpha’s Quant Rating on Cel-Sci Historical earnings data for Cel-Sci Financial information for Cel-Sci For further details see: CEL-SCI climbs after ESMO data for lead asset Multikine

CVM - CVM, AUMN and SLNH among mid-day movers

2023-10-23 13:18:40 ET Gainers: LumiraDx Limited ( LMDX ) +186% . Akumin ( AKU ) +178% . Textainer Group Holdings Limited ( TGH ) +44% . Cel-Sci Corp. ( CVM ) +41% . ImmunoPrecise Antibodies Ltd ( IPA ) +27% . Soluna Holdings...
CVM - 24/7 Market News Lunch Break 23 Oct 2023

2023-10-23 12:19:40 ET DENVER, Colo., Oct. 23, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; LumiraDx Ltd (NASDAQ: LMDX), CEL-SCI Corp (AMEX: CVM), Inpixon (NASDAQ: INPX), INVO Bioscience Inc (NA...

CVM - 5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

Target patient population for regulatory submissions finalized: Patients with low PD-L1 , in contrast to current checkpoint inhibitors which work best with high PD-L1. Addressing unmet need in ~145,000 head and neck cancer patients per year worldwide. Routine cancer sc...

CVM - CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production

Achieves significant milestones toward commissioning of manufacturing facility in preparation for Biologics License Application for regulatory approval submissions CEL-SCI Corporation (NYSE American: CVM) today reported that its Multikine* (Leukocyte Interleukin, Injection) cGMP s...
CVM - CEL-SCI Files Request With the UK's MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI will present the MHRA with new results that demonstrate pre-surgical response rates and overall survival advantages that are superior to those published by CEL-SCI previously, as a result of an improved selection algorithm that more accurately predicts the patients who would benef...

CVM - CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer

Europe has 150,000 new head & neck cancer cases each year, more than twice the incidence in the U.S. CEL-SCI Corporation (NYSE American: CVM) today reported it has filed a request for Scientific Advice regarding Multikine* (Leukocyte Interleukin, Injection) immunotherapy for t...

CVM - Cel-Sci GAAP EPS of -$0.57

2023-08-11 08:47:18 ET Cel-Sci press release ( NYSE: CVM ): Q2 GAAP EPS of -$0.19. For further details see: Cel-Sci GAAP EPS of -$0.57
Previous 10 Next 10